

Jay M Edelberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2198788/publications.pdf>

Version: 2024-02-01

60
papers

6,864
citations

136885

32
h-index

149623

56
g-index

61
all docs

61
docs citations

61
times ranked

7998
citing authors

#	ARTICLE	IF	CITATIONS
1	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
2	Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. <i>Nature Medicine</i> , 1999, 5, 1010-1017.	15.2	519
3	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 759-769.	6.3	481
4	Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-deficient Mice. <i>Circulation Research</i> , 2002, 90, 270-276.	2.0	461
5	Young Adult Bone Marrow-derived Endothelial Precursor Cells Restore Aging-Impaired Cardiac Angiogenic Function. <i>Circulation Research</i> , 2002, 90, E89-93.	2.0	290
6	Vascular Bed-specific Expression of an Endothelial Cell Gene Is Programmed by the Tissue Microenvironment. <i>Journal of Cell Biology</i> , 1997, 138, 1117-1124.	2.3	261
7	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 618-628.	5.5	207
8	Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2649-2660.	1.2	176
9	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	1.2	154
10	Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14222-14227.	3.3	152
11	Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model. <i>Circulation</i> , 2002, 105, 608-613.	1.6	138
12	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	1.2	131
13	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). <i>American Journal of Cardiology</i> , 2017, 119, 40-46.	0.7	116
14	Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. <i>Thrombosis Research</i> , 1990, 57, 155-162.	0.8	113
15	Purification of Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase. <i>Journal of Biological Chemistry</i> , 1996, 271, 27072-27082.	1.6	112
16	Stem Cells and the Regeneration of the Aging Cardiovascular System. <i>Circulation Research</i> , 2007, 100, 1116-1127.	2.0	112
17	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
18	Endothelial microparticles: Sophisticated vesicles modulating vascular function. <i>Vascular Medicine</i> , 2013, 18, 204-214.	0.8	79

#	ARTICLE	IF	CITATIONS
19	Vascular tenascin ϵ regulates cardiac endothelial phenotype and neovascularization. <i>FASEB Journal</i> , 2006, 20, 717-719.	0.2	74
20	Impaired Angiogenesis in the Aged. <i>Science of Aging Knowledge Environment: SAGE KE</i> , 2004, 2004, 7pe-7.	0.9	72
21	A murine model of myocardial microvascular thrombosis. <i>Journal of Clinical Investigation</i> , 1999, 104, 533-539.	3.9	62
22	Bone Marrow Oct3/4+Cells Differentiate Into Cardiac Myocytes via Age-Dependent Paracrine Mechanisms. <i>Circulation Research</i> , 2007, 100, e1-11.	2.0	61
23	Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133+Stem Cells Into Angiomyogenic Tissue. <i>Circulation</i> , 2005, 111, 1175-1183.	1.6	58
24	BDNF-mediated enhancement of inflammation and injury in the aging heart. <i>Physiological Genomics</i> , 2006, 24, 191-197.	1.0	58
25	Aging ϵ Associated Changes in Vascular Activity: A Potential Link to Geriatric Cardiovascular Disease. <i>The American Journal of Geriatric Cardiology</i> , 2001, 10, 348-354.	0.7	51
26	Green fluorescent protein selectively induces HSP70-mediated up-regulation of COX-2 expression in endothelial cells. <i>Blood</i> , 2003, 102, 2115-2121.	0.6	49
27	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
28	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1649-1658.	2.9	49
29	Senescent Impairment in Synergistic Cytokine Pathways That Provide Rapid Cardioprotection in the Rat Heart. <i>Journal of Experimental Medicine</i> , 2004, 199, 797-804.	4.2	48
30	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	1.0	45
31	Vulnerable Atherosclerotic Plaque: Clinical Implications. <i>Current Vascular Pharmacology</i> , 2003, 1, 183-204.	0.8	41
32	Regulation of Vascular Bed ϵ Specific Prothrombotic Potential. <i>Circulation Research</i> , 2001, 89, 117-124.	2.0	36
33	Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. <i>American Heart Journal</i> , 2021, 239, 80-89.	1.2	35
34	A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats. <i>Coronary Artery Disease</i> , 2005, 16, 407-410.	0.3	29
35	Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 329-337.	0.7	26
36	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 ϵ years. <i>Journal of Clinical Lipidology</i> , 2017, 11, 986-997.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Platelet-derived growth factor improves cardiac function in a rodent myocardial infarction model. <i>Coronary Artery Disease</i> , 2004, 15, 59-64.	0.3	16
38	Stem Cell Review Series: Regulating highly potent stem cells in aging: environmental influences on plasticity. <i>Aging Cell</i> , 2008, 7, 599-604.	3.0	15
39	Stem cells for cardiovascular repair – The challenges of the aging heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 582-592.	0.9	15
40	Age-related differences in repair of dermal wounds and myocardial infarcts attenuate during the later stages of healing. <i>In Vivo</i> , 2006, 20, 801-6.	0.6	14
41	Translation of PDGF Cardioprotective Pathways. <i>Cardiovascular Toxicology</i> , 2003, 3, 27-36.	1.1	13
42	Endothelial Precursor Cells. <i>Stem Cell Reviews and Reports</i> , 2007, 3, 218-225.	5.6	12
43	Harnessing Hormonal Signaling for Cardioprotection. <i>Science of Aging Knowledge Environment: SAGE KE</i> , 2005, 2005, re6-re6.	0.9	12
44	Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 1115-1123.	1.0	11
45	Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: The effects of ionic strength, divalent cations, and chloride. <i>Archives of Biochemistry and Biophysics</i> , 1992, 296, 530-538.	1.4	9
46	Enhanced myocyte-based biosensing of the blood-borne signals regulating chronotropy. <i>Journal of Applied Physiology</i> , 2002, 92, 581-585.	1.2	9
47	Quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling. <i>Physiological Genomics</i> , 2006, 26, 202-208.	1.0	9
48	Navigating the Future of Cardiovascular Drug Development – Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 445-458.	1.3	8
49	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e016506.	1.6	8
50	Vascular Regulation of Plasminogen Activator Inhibitor-1 Activity. <i>Seminars in Thrombosis and Hemostasis</i> , 1994, 20, 319-323.	1.5	6
51	Phage display identification of age-associated TNF α -mediated cardiac oxidative induction. <i>Physiological Genomics</i> , 2004, 18, 255-260.	1.0	6
52	PDGF-AB-based functional cardioprotection of the aging rat heart. <i>Experimental Gerontology</i> , 2006, 41, 63-68.	1.2	5
53	Genetically Engineered Biologically Based Hemostatic Bioassay. <i>Annals of Biomedical Engineering</i> , 2003, 31, 159-162.	1.3	4
54	[17] Lipoprotein (a): Purification and kinetic analysis. <i>Methods in Enzymology</i> , 1993, 223, 272-288.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Auto Repair on the Aging Stem Cell Superhighway. Science of Aging Knowledge Environment: SAGE KE, 2002, 2002, 13pe-13.	0.9	2
56	Vascular pathology and repair in the aging heart: alterations in inflammatory mediators. Drug Discovery Today Disease Mechanisms, 2004, 1, 59-64.	0.8	1
57	Lowering LDL-C with alirocumab, an investigational PCSK9 inhibitor. Clinical Lipidology, 2014, 9, 603-606.	0.4	0
58	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. Journal of Clinical Lipidology, 2019, 13, e54-e55.	0.6	0
59	POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES. Journal of the American College of Cardiology, 2019, 73, 2034.	1.2	0
60	A quantitative approach to phage display analysis for molecular profiling of vascular heterogeneity. FASEB Journal, 2006, 20, A32.	0.2	0